ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Alvotech due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Alvotech's stock price experienced a significant decline of 34% on November 3, 2025, following the announcement of a complete response letter (CRL) from the U.S. FDA regarding its Biologics License Application for AVT05 [3]. - The CRL indicated that certain deficiencies identified during the FDA's pre-license inspection of Alvotech's Reykjavik manufacturing facility must be resolved before the BLA for AVT05 can be approved [3]. Group 2: Legal Actions - Investors who purchased Alvotech securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Alvotech [2]. Group 3: Rosen Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].